Tranylcypromine
ترانیلسیپرومین
🧠 Nervous SystemMAO inhibitor (non-selective)
Market / country: 🇺🇸 USA
Parnate (US)
🧮 Dose calculator
Major depressive disorder · Regimen source: FDA Tranylcypromine · 2.1
- • If inadequate: +10 mg/day every 1–3 weeks to max 30 mg twice daily. Check BP and history of mania first. Taper (delirium on abrupt stop). Washout with other antidepressants per 2.2. FDA Tranylcypromine · 2.1FDA Tranylcypromine · 2.4FDA Tranylcypromine · 2.3FDA Tranylcypromine · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Other MAOIs, SSRIs, SNRIs, tricyclics, sympathomimetics and many other drugs (label Table 1); pheochromocytoma or catecholamine-releasing paraganglioma. FDA Tranylcypromine · 4
Warnings
- • Boxed warning: suicidality in children and young adults; hypertensive crisis with significant tyramine intake (aged cheese, cured meats…). FDA Tranylcypromine · Boxed Warning
- • Serotonin syndrome; mania; hypotension; hepatotoxicity; seizures; hypoglycaemia in diabetics. FDA Tranylcypromine · 5
Formulations
- 10 mg tablet — tablet 🇺🇸 USA FDA Tranylcypromine · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tranylcypromine · 8.1
“Risk Summary There are limited published reports of placental infarction and congenital anomalies in association with use of tranylcypromine sulfate tablets during pregnancy; however, these reports may not adequately inform the presence or absence of drug-associated risk with the use of tranylcypromine sulfate tablets …”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Tranylcypromine · 8.2
“Risk Summary Tranylcypromine is present in human milk.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Tranylcypromine · Boxed Warning
“Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tranylcypromine · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA012342
- DailyMed (FDA label)FDA Tranylcypromine
- MedlinePlus (NIH)Tranylcypromine
- WHO ATC/DDDN06AF04
- Darooyab (Iran)Tranylcypromine
🇮🇷 Registered in Iran Darooyab · G-613/Tranylcypromine
Dosage forms with Iranian generic codes, per Darooyab.
- 01241 · TRANYLCYPROMINE 10MG TAB · قرص ترانیلسیپرومین ۱۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Tranylcypromine · 3FDA Tranylcypromine · 2.1FDA Tranylcypromine · 2.4FDA Tranylcypromine · 2.3FDA Tranylcypromine · 2.2FDA Tranylcypromine · 4FDA Tranylcypromine · Boxed WarningFDA Tranylcypromine · 5FDA Tranylcypromine · SPL approval / marketing categoryFDA Tranylcypromine · 8.1FDA Tranylcypromine · 8.2FDA Tranylcypromine · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-613/Tranylcypromine
- Clinical review⚠ Unverified